Clinical Trial: Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery

U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07912801) titled 'Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery' on Oct. 28.

Brief Summary: Myocardial injury and infarction are common after cardiac surgery and are associated with worse perioperative outcomes. Hypoxia-inducible factor (HIF) is an important metabolic regulator that protects the myocardium. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved for the treatment of anemia of chronic kidney disease; it enhances the hypoxia-protective pathway and erythropoiesis. We hypothesize that, in patients undergoing off-pump coronary artery bypass grafting (CABG), preoperativ...